USPTO serial 88292621
BIO3CBD
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- MURRAY, GEORGE WILLIAM
- Law office
- TMO LAW OFFICE 121 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with BIO3CBD?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Andrew D. Price
Andrew D. Price Venable LLPP.O. Box 34385Washington, DC 20043-9998UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | dietary and nutritional supplements, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; ingredients for dietary and nutritional supplements, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; dietary and nutritional supplements featuring an ingredient whose primary purpose is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; topical creams, gels, salves, sprays, powders, oils, tinctures, balms and ointments, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; ingredients for topical creams, gels, salves, sprays, powders, oils, tinctures, balms and ointments, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; topical creams, gels, salves, sprays, powders, oils, tinctures, balms and ointments featuring an ingredient whose primary purpose is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; pharmaceuticals, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; ingredients for pharmaceuticals, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; pharmaceuticals featuring an ingredient whose primary purpose is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; dietetic foods, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; ingredients for dietetic foods, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; dietetic foods featuring an ingredient whose primary purpose is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; dietetic beverages, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; ingredients for dietetic beverages, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; dietetic beverages featuring an ingredient whose primary purpose is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; functional beverages, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; ingredients for functional beverages, the primary purpose of which is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease; functional beverages featuring an ingredient whose primary purpose is to reduce inflammation, relieve aches and pains, improve cognitive health, alleviate symptoms of attention deficit/hyperactivity disorder and post-traumatic stress disorder, improve overall health and reduce the risk of disease | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 13, 2020 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Oct 13, 2020 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Mar 24, 2020 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 24, 2020 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 24, 2020 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 11, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 11, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 11, 2020 | ALIE | ASSIGNED TO LIE | — |
| Mar 5, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 12, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 12, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 12, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 9, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 7, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 1, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 11, 2019 | NWAP | NEW APPLICATION ENTERED | — |